Approvals

Sanofi gets EC approval for blood-clotting disorder drug Cablivi

Sanofi has secured marketing approval from the European Commission for its Cablivi (caplacizumab) to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP).

FDA approves Bayer’s Jivi for Hemophilia A patients aged 12 and older

The US Food and Drug Administration (FDA) has approved Jivi (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.

Merck secures FDA approval for two HIV drugs

Merck has secured approval from the US Food and Drug Administration (FDA) for its two new HIV-1 treatments, Delstrigo and Pifeltro.

EC grants orphan drug status to Trovagene’s Onvansertib for AML treatment

Trovagene has announced that the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and granted orphan drug designation (ODD) for Onvansertib to treat patients with acute myeloid leukemia (AML).

Novartis’ Kymriah CAR-T cell therapy secures European approval

Novartis has secured the European Commission (EC) approval for its CAR-T cell therapy Kymriah (tisagenlecleucel) for the treatment of B-cell acute lymphoblastic leukemia.

FDA approves Tetraphase’s Xerava for complicated intra-abdominal infections

Tetraphase Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its Xerava (eravacycline) to treat complicated intra-abdominal infections (cIAI).

Bayer secures approval in EU for Xarelto for patients with coronary or peripheral artery disease

The European Commission (EC) has approved a combination of Xarelto (rivaroxaban) 2.5mg twice daily plus low dose aspirin (acetylsalicylic acid/ASA) once daily for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral arterial disease (PAD) at high risk of ischaemic events.

FDA approves Shire’s hereditary angioedema drug Takhzyro

Shire has secured approval from the US Food and Drug Administration (FDA) for Takhzyro (lanadelumab-flyo) injection as a preventative treatment of hereditary angioedema (HAE) in patients 12 years of age and older.

FDA approves Dompé’s Oxervate to treat neurotrophic keratitis

Dompé has secured approval from the US Food and Drug Administration (FDA) for its Oxervate (cenegermin-bkbj ophthalmic solution) to treat neurotrophic keratitis (NK).